Guardant Health and Hikma Partner for Cancer Screening and Genomic Profiling in the Middle East and North Africa

Monday, January 08, 2024

Guardant Health, Inc. (Nasdaq: GH) and Hikma Pharmaceuticals PLC have recently forged a partnership to promote the suite of liquid and tissue biopsy tests by Guardant Health for cancer screening and monitoring across the Middle East and North Africa (MENA) region. This collaboration marks an expansion of Guardant Health's global outreach, with Hikma securing exclusive rights to commercialize these products in most MENA countries.

The comprehensive range of tests includes Shield™ for cancer screening, Guardant Reveal™ for disease detection and recurrence monitoring, and Guardant360® and Guardant360 TissueNext™ for comprehensive genomic profiling. This joint effort seeks to improve accessibility to Guardant's next-generation sequencing (NGS) tests in a region where the incidence of cancer is projected to double by 2040.

Guardant Health is eager to leverage Hikma's commercial expertise to provide essential tools for oncologists in MENA, addressing the growing challenge of detecting advanced-stage cancer cases and ensuring timely treatment selection. As a prominent healthcare entity in MENA with a robust portfolio covering generics, biologics, immunotherapy, and cutting-edge innovations, Hikma is committed to advancing precision medicine for enhanced treatment outcomes in cancer patients.





Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare Innovation & Transformation SummitHealthcare CNO SummitHealthcare CMO SummitThe Healthcare Patient Experience & Engagement Summit 2024